Copenhagen Oe

• LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended recruitment
  2024-510742-13-00 5 2023-04-19 Pediatric low-grade glioma harboring an activating RAF alteration requ
• Biologic treatment of rhinosinusitis with nasal polyposis in real-world Danish patients - a direct comparison of dupilumab and mepolizumab Ended recruitment
  2022-502250-14-00 6 2023-04-13 Chronic rhinosinusitis with nasal polyposis
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas … Ended recruitment
  2023-503444-13-00 5 2023-03-29 Relapsed/refractory multiple myeloma
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• Bicarbonate for the treatment of cardiac arrest Ended recruitment
  2022-501304-10-00 6 2023-02-06 In-hospital cardiac arrest
• A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants with Prodromal and Early Manife … Ended recruitment
  2023-503928-10-00 4 2023-02-01 Prodromal and Early Manifest Huntington’s Disease
• Long-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials Ended recruitment
  2024-511707-42-00 5 2023-01-05 Spinal Muscular Atrophy
• Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy Ended recruitment
  2022-500090-13-00 4 2022-12-29 Becker Muscular Dystrophy (BMD)
• A Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants with Facioscapul … Ended recruitment
  2022-503117-36-00 4 2022-12-01 Facioscapulohumeral muscular dystrophy (FSHD)
• Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Ended recruitment
  2023-508284-77-00 5 2022-11-16 Generalized Myasthenia Gravis with autoantibodies against acetylcholin
• A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria Ended recruitment
  2023-509229-31-00 5 2022-09-28 Metabolic Disorders - Phenylketonuria
• A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL Ended recruitment
  2023-504187-42-00 1 2022-09-12 Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
• ATA-100 gene therapy trial in patients with limb-girdle muscular dystrophy Ended recruitment
  2023-506677-36-00 7 2022-07-18 FKRP-related limb-girdle muscular dystrophy (LGMD R9)
• A Study to Evaluate Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone o … Ended recruitment
  2023-507019-36-00 3 2022-07-08 Relapsed or Refractory Multiple Myeloma (R/R MM)
• A study to evaluate the effect of venglustat tablets on neuropathic and abdominal pain in male and female participants ≥16 years of age with … Ended recruitment
  2024-511990-31-00 5 2022-06-28 Fabry Disease
• The RESCUE study Ended recruitment
  2024-518272-30-00 6 2022-06-01 Glucocorticoid induced adrenal insufficiency
• Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Ki … Ended recruitment
  2024-515024-37-00 5 2022-05-27 Pyruvate Kinase Deficiency
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended recruitment
  2024-512745-16-00 5 2022-04-13 Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
• Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended recruitment
  2023-506361-56-00 5 2022-04-01 Endometrial cancer
• Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended recruitment
  2023-504597-37-00 5 2022-03-25 Focal segmental glomerulosclerosis
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended recruitment
  2023-503640-14-00 5 2022-02-17 Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b … Ended recruitment
  2023-504884-17-00 5 2022-02-04 Proteinuria
• A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC). Ended recruitment
  2024-511837-37-00 4 2021-12-21 Relapsed/Refractory Small Cell Lung Cancer

Showing 433–456 of 671 trials